AirSculpt Technologies, Inc. Announces Executive Leadership Changes & Reiterates 2022 Revenue Guidance
07 January 2023 - 12:00AM
AirSculpt Technologies, Inc., (“AirSculpt” or the “Company”)
(NASDAQ: AIRS) an industry leader and provider of premium body
contouring procedures, announced today that AirSculpt Founder and
current Chief Executive Officer, Dr. Aaron Rollins, will become
Executive Chairman of the Board of Directors. Dr. Rollins will be
primarily focused on leading the Company’s overall vision and
providing strategic guidance.
In addition, the Company announced today that Todd Magazine has
been appointed Chief Executive Officer. Mr. Magazine will
work closely with Dr. Rollins to develop and execute the company’s
growth strategy. He will assume CEO responsibilities at
the end of January.
"I am thrilled to announce the addition of Todd to our team,"
said Dr. Rollins. "He is a seasoned strategic leader and
brings a wealth of experience to guide our team in scaling our
business both domestically and internationally. Our complementary
skillsets bring a new level of excellence to the company."
"I am very excited about working with Dr. Rollins and the team
to build upon an already strong foundation of success," said Mr.
Magazine. "There is a tremendous opportunity to increase
growth by leveraging AirSculpt's proprietary technology and premium
experience, as well as by building awareness of the brand. I
have no doubt AirSculpt will be the market leader in body
contouring very soon." Mr. Magazine brings to AirSculpt more
than 30 years of experience in retail operations and
brand-building. For the past 10 years, he has been the CEO of Blink
Fitness, a subsidiary of Equinox, where he led the company of over
1,500 employees from four locations to over 100 and increased
membership 25x. Prior to that, he was North American President of
Pfizer's OTC business, held president's roles for Gatorade and
Quaker Oats at PepsiCo, and led various marketing teams at Procter
& Gamble. Mr. Magazine received a BA from The University of
Michigan and his MBA from Northwestern University's Kellogg School
of Management.
The Company also reiterated its full-year 2022 revenue guidance
of $168-$170 million.
Investor Contact:
Steven Halper/Caroline PaulManaging Directors, LifeSci
Advisorsinvestors@elitebodysculpture.com
Media Contact:
Stephanie Evans GreeneChief Marketing OfficerAirSculpt
Technologies, Inc.sevansgreene@elitebodysculpture.com
About AirSculptAirSculpt (NASDAQ: AIRS) is an experienced,
fast-growing international provider of body contouring procedures
delivering a premium consumer experience under its brand, Elite
Body Sculpture. At Elite Body Sculpture, we provide custom body
contouring using our proprietary AirSculpt® method that removes
unwanted fat in a minimally invasive procedure, producing dramatic
results. It is our mission to generate the best results for our
patients.
Forward-Looking Statements
This press release contains forward-looking statements. In some
cases, you can identify these statements by forward-looking words
such as “may,” “might,” “will,” “should,” “expects,” “plans,”
“anticipates,” “believes,” “estimates,” “predicts,” “potential” or
“continue,” the negative of these terms and other comparable
terminology. These forward-looking statements, which are subject to
risks, uncertainties, and assumptions about us, may include
projections of our future financial performance, our anticipated
growth strategies, and anticipated trends in our business. These
statements are only predictions based on our current expectations
and projections about future events. There are important factors
that could cause our actual results, level of activity,
performance, or achievements to differ materially from the results,
level of activity, performance or achievements expressed or implied
by the forward-looking statements, including those factors
discussed in the section titled “Risk Factors” in our Annual Report
on Form 10-K and our Quarterly Report on Form 10-Q for the quarter
ended September 30, 2022.
Our future results could be affected by a variety of other
factors, including, but not limited to, failure to open and operate
new centers in a timely and cost-effective manner; shortages or
quality control issues with third-party manufacturers or suppliers;
competition for surgeons; litigation or medical malpractice claims;
inability to protect the confidentiality of our proprietary
information; changes in the laws governing the corporate practice
of medicine or fee-splitting; changes in the regulatory, economic
and other conditions of the states and jurisdictions where our
facilities are located; and business disruption or other losses
from war, pandemic, terrorist acts or political unrest.
The risk factors discussed in “Risk Factors” in our Annual
Report on Form 10-K and our Quarterly Report on Form 10-Q for the
quarter ended September 30, 2022 could cause our results to differ
materially from those expressed in the forward-looking statements
made in this press release.
There also may be other risks that are currently unknown to us
or that we are unable to predict at this time.
Although we believe the expectations reflected in the
forward-looking statements are reasonable, we cannot guarantee
future results, level of activity, performance, or achievements.
Moreover, neither we nor any other person assumes responsibility
for the accuracy and completeness of any of these forward-looking
statements. Forward-looking statements speak only as of the date
they were made, and we are under no duty to update any of these
forward-looking statements after the date of this press release to
conform our prior statements to actual results or revised
expectations.
AirSculpt Technologies (NASDAQ:AIRS)
Historical Stock Chart
From Mar 2024 to Apr 2024
AirSculpt Technologies (NASDAQ:AIRS)
Historical Stock Chart
From Apr 2023 to Apr 2024